Acasti Pharma (NASDAQ:ACST) and the FDA agreed on the protocol of a Phase 3 trial of GTX-104 in patients with aneurysmal subarachnoid hemorrhage (aSAH), a rare disease with bleeding over the surface of the brain in the...
Search results for - ACST
Acasti submits Phase 3 safety protocol; implements strategic realignment
Acasti Pharma (NASDAQ:ACST) submitted to the FDA the full protocol of its GTX-104 for a Phase 3 safety study of a rare disease, aneurysmal subarachnoid hemorrhage, and implementation of a strategic realignment plan to...
Acasti Pharma transitions to orphan diseases from cardiovascular
After a failed Phase 3 trial in August 2020 with its CaPre lead drug candidate for patients with severe hypertriglyceridemia, Acasti Pharma (NASDAQ, TSXV:ACST) has transitioned into the rare and orphan disease sector...
Echelon cuts Acasti Pharma to sell; PT to 15 cents
Echelon Wealth Partners downgraded Acasti Pharma (TSXV:ACST) to “sell” from “speculative buy” and slashed its price target to 15 cents (Canadian) from $1.40 after the company reported that its Phase 3 TRILOGY 2 trial...
HCW halves Acasti Pharma PT to $3 from $6
H.C. Wainwright halved its price target for Acasti Pharma (NASDAQ:ACST) to $3 from $6 in light of the continued uncertainty around the company’s TRILOGY 1 and TRILOGY 2 trials. The stock closed at 57 cents on Feb. 14...
Mackie puts Acasti Pharma under review; removes PT
Mackie Research Capital put Acasti Pharma (NASDAQ, TSXV:ACST) “under review” and removed its price target after the company’s pivotal TRILOGY-1 trial missed its primary endpoint because of an unexplained high placebo...
Echelon reiterates Acasti Pharma, Antibe Therapeutics as top picks
Echelon Wealth Partners reiterated top pick status to Acasti Pharma (TSXV:ACST) and Antibe Therapeutics (TSXV:ATE). Acasti is developing an omega-3-based therapeutic for the treatment of hyperglyceridemia. Analyst Doug...
HCW starts 2 omega-3 companies at buy
H.C. Wainwright launched coverage of Acasti Pharma (NASDAQ:ACST) and Matinas BioPharma (NYSE American:MTNB) with “buy” ratings and price targets of $6 and $4, respectively.